Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
|
+$247M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$188M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$112M |
| 4 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$91.9M |
| 5 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$75.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$67.4M |
| 2 |
XOMA
Xoma
XOMA
|
+$26.3M |
| 3 |
AMBI
Ambit Biosciences Corp
AMBI
|
+$16.8M |
| 4 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$14.3M |
| 5 |
RPRX
Repros Therapeutics Inc.
RPRX
|
+$6.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
101
DELISTED
Acceleron Pharma
XLRN
| $1.12M | 0.01% |
28,765
| – | – |
|
102
Rigel Pharmaceuticals
RIGL
$857M
| $1.09M | 0.01% |
48,197
| – | – |
|
103
Arcturus Therapeutics
ARCT
$382M
| $1.08M | 0.01% |
+41,410
| New | +$1.32M |
|
104
Alaunos Therapeutics
TCRT
$4.47M
| $982K | 0.01% |
1,291
-340
| -21% | -$180K |
|
|
FPRX
105
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $535K | 0.01% |
19,823
| – | – |
|
106
uniQure
QURE
$3.36B
| $454K | ﹤0.01% |
30,672
| – | – |
|
|
CCXI
107
DELISTED
ChemoCentryx, Inc.
CCXI
| $342K | ﹤0.01% |
50,000
| – | – |
|
|
AST
108
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
| $54K | ﹤0.01% |
+16,775
| New | +$67.5K |
|
|
BTX.WS
109
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
| $22K | ﹤0.01% |
+20,525
| New | +$22.2K |
|
|
AVNR
110
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
| – | – |
-9,356,200
| Closed | -$112M |
|
|
AMBI
111
DELISTED
Ambit Biosciences Corp
AMBI
| – | – |
-1,093,332
| Closed | -$16.8M |
|
Similar funds
Julian Baker's Q4 2014 Portfolio in Review
As of Q4 2014, Julian Baker held 123 positions worth $9.8B, up 23% from $7.94B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Julian Baker withdrew a net $1.4B in Q4 2014, closing 2 positions and reducing 12 holdings. Its most notable exit was Ambit Biosciences Corp, an estimated $16.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 44% a quarter earlier.
Against the trend, Julian Baker opened a new position in Bellicum Pharmaceuticals, Inc. worth $98.7M.
- Julian Baker's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 428,373 shares worth $98.7M.
- Julian Baker added most to AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, an estimated $247M increase.
- Julian Baker's biggest Q4 2014 reduction was PHARMACYCLICS INC, cutting an estimated $67.4M.
- Julian Baker fully exited Ambit Biosciences Corp in Q4 2014, selling an estimated $16.8M.
- Julian Baker's ten largest holdings make up 73% of its $9.8B portfolio in Q4 2014.
- Julian Baker opened 14 new positions and closed 2 in Q4 2014.
- Julian Baker's portfolio value rose 23% quarter-over-quarter to $9.8B.
Based on Baker Bros. Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.